You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Toxicity management for patients receiving novel T-cell engaging therapies
|
|---|---|
| Published in |
Current opinion in pediatrics, February 2014
|
| DOI | 10.1097/mop.0000000000000043 |
| Pubmed ID | |
| Authors |
David M. Barrett, David T. Teachey, Stephan A. Grupp |
| Abstract |
Recent clinical trials using T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cells, as well as engineered T cells that express targeting and activation molecules known as chimeric antigen receptors, have demonstrated powerful proof of concept. These therapies result in a significant degree of immune activation in the patient, which has correlated with greatly increased efficacy but also with notable toxicity. These therapies produce nonphysiologic T-cell activation, which is the hallmark of these new, highly active treatments. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 115 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 114 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 17% |
| Student > Ph. D. Student | 15 | 13% |
| Student > Master | 13 | 11% |
| Student > Bachelor | 10 | 9% |
| Other | 10 | 9% |
| Other | 17 | 15% |
| Unknown | 31 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 25% |
| Biochemistry, Genetics and Molecular Biology | 12 | 10% |
| Agricultural and Biological Sciences | 12 | 10% |
| Immunology and Microbiology | 10 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Other | 16 | 14% |
| Unknown | 28 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2023.
All research outputs
#2,637,305
of 25,540,105 outputs
Outputs from Current opinion in pediatrics
#119
of 1,444 outputs
Outputs of similar age
#29,898
of 323,452 outputs
Outputs of similar age from Current opinion in pediatrics
#2
of 11 outputs
Altmetric has tracked 25,540,105 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,444 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,452 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.